Effect of IL-1 Blockade With Anakinra on Heart Failure Outcomes in Patients With Anterior Versus Nonanterior ST...

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• ST-elevation myocardial infarction (STEMI) patients face significant risk of developing heart failure (HF).
• Interleukin-1 (IL-1), a key inflammatory mediator, plays a crucial role in post-myocardial infarction complications.
• IL-1 blockade presents a potential therapeutic avenue for preventing HF post-STEMI.

Purpose of the Study:

• To investigate the efficacy of anakinra, an IL-1 receptor antagonist, in mitigating HF outcomes in STEMI patients.
• To assess whether anakinra's effects differ based on the location of STEMI (anterior vs. nonanterior).
• To determine if anakinra improves left ventricular systolic function and cardiac remodeling post-STEMI.

Main Methods:

• Pooled analysis of data from three early-phase randomized clinical trials.
• Identification of anterior STEMI based on the left anterior descending coronary artery as the culprit vessel.
• Primary endpoint: composite of all-cause death and new-onset HF at 1-year follow-up.

Main Results:

• Anakinra significantly reduced the composite endpoint of death or new-onset HF in both anterior STEMI (13% vs. 42%, P=0.049) and nonanterior STEMI (6% vs. 24%, P=0.014) groups.
• No significant differences were observed in the interval changes of left ventricular ejection fraction and volumes between anakinra and placebo groups.
• The beneficial effect of anakinra on HF events was consistent across STEMI locations.

Conclusions:

• Anakinra demonstrates a significant reduction in heart failure events among STEMI patients.
• This therapeutic benefit is independent of the STEMI location (anterior vs. nonanterior).
• Anakinra's protective effect on HF outcomes is not mediated through significant improvements in left ventricular ejection fraction or cardiac remodeling in this cohort.